Larry D Lynd

The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study

Anna Lehman, Jan M Friedman, Nick Dragojlovic, 2018, Genetics in Medicine.

Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.

Mark J Sculpher, Andrew R Willan, Mehdi Najafzadeh, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme

David Patrick, Carlo A Marra, Larry D Lynd, 2010, Sexually Transmitted Infections.

A discrete choice experiment evaluation of patients’ preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management

Scot Simpson, Carlo A Marra, Graydon Meneilly, 2010, Patient preference and adherence.

Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE)

Mehdi Najafzadeh, Carlo A Marra, Marco A Marra, 2013, BMC Health Services Research.

Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis.

Larry D Lynd, B. O'brien, L. Lynd, 2004, Journal of clinical epidemiology.

A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net‐benefit framework

Mohsen Sadatsafavi, Mehdi Najafzadeh, Carlo A Marra, 2010, Pharmacoepidemiology and drug safety.